Pharmacologic induction of fetal hemoglobin: Raising the therapeutic bar in sickle cell disease

Current Opinion in Hematology

Volumn 8, Issue 2, 2001, Pages 123-130

  Atweh, G F ^a   Schechter, A N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUTYRIC ACID; DROXIA; HEMOGLOBIN F; HYDROXYUREA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA METHYLATION; DRUG POTENTIATION; GENE CONTROL; GLOBIN GENE; HEMOGLOBIN DETERMINATION; HEMOGLOBIN SYNTHESIS; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; AZACITIDINE; BUTYRATES; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA;

EID: 0035094512     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200103000-00010     Document Type: Article

References (47)

1. The significance of the paucity of sickle cells in newborn negro infants
2. Physiological decline in fetal hemoglobin parameters in infants with sickle cell disease: Implications for pharmacological intervention
3. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
4. Pain in sickle cell disease: Rates and risk factors
5. Mortality in sickle cell disease: Life expectancy and risk factors for early death
6. Sickle cell disease pathophysiology
7. Reperfusion injury pathophysiology in sickle transgenic mice
8. Hypoxia/reoxygenation causes inflammatory response in transgenic mice but not in normal mice
9. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiological ligand saturations
10. Hemoglobin S polymerization: Primary determinant of the hemolytic and clinical severity of the sickling syndromes
11. Levels of fetal hemoglobin necessary for treatment of sickle cell disease
12. 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia
13. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: Dose-response analysis of subcutaneous and oral dosage regimens
14. Augmentation of fetal-hemoglobin production in anemic monkey by hydroxyurea
15. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia
16. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia
17. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea
18. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
19. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea
20. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia
21. Progressive pulmonary hypertension and pulmonary insufficiency in sickle cell patients who respond to hydroxyurea
22. From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera
23. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
24. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
25. Pharmacological Therapy
26. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients
27. Bone marrow transplantation for hemoglobinopathies
28. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial
29. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea
30. Hydroxyurea and sickle cell anemia: Clinical utility of a myelosuppressive "switching" agent
31. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate
32. Delay in the fetal globin switch in infants of diabetic mothers
33. The relative rates of fetal and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers
34. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching
35. α-Amino-N-butyric acid stimulates fetal hemoglobin in the adult
36. A short-term trial of butyric acid to stimulate fetal-globin-gene expression in the β-globin disorders
37. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies
38. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
39. Oral sodium phenylbutyrate therapy in homozygous β-thalassemia: A clinical trial
40. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
41. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
42. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression
43. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia
44. Absence of cross-resistance to the HbF stimulating activities of butyrate and hydroxyurea
45. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease
46. Riosk and benefits of hydroxyurea (HU) in adult sickle cell anemia: Effects at 6 to 7 months